FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| The Effect of Forgiveness Psychoeducation on Forgiveness, Self-Compassion and Death Anxiety in Cancer Patients: A Randomized Controlled Trial. PMID 40663159 · Omega (Westport) · 2025-Jul-15 The record reports a randomized controlled trial in oncology patients, but it tests a non-drug intervention (forgiveness psychoeducation) and its endpoints are psychological outcomes, not time-to-event efficacy measures. Therefore, it does not meet the criteria for inclusion in the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Perioperative administration of CBM588 in colorectal cancer radical surgery: A single-center, randomized controlled trial. PMID 40633539 · Cell Rep Med · 2025-Jul-15 The study is a Phase IV randomized controlled trial in colorectal cancer with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The endpoints are postoperative functional recovery and immune status, not survival or progression-based outcomes. Therefore, it is ineligible for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800). PMID 40614118 · Cancer · 2025-Jul-15 The record is excluded because it does not meet the required phase criterion (one trial is Phase 3b, the other is Phase 2, and the combined record is not a single definitive Phase III/IIIb or Phase II/III trial) and lacks a time-to-event efficacy endpoint. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study. PMID 40450840 · J Neurol Sci · 2025-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial. PMID 40242960 · Aesthet Surg J · 2025-Jul-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Esaxerenone Plus a Renin-Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis. PMID 40178088 · Am J Hypertens · 2025-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial. PMID 40079683 · Int J Cancer · 2025-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study. PMID 39949051 · Gut Liver · 2025-Jul-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Novel Y-Shaped Pegylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency. PMID 39607675 · J Clin Endocrinol Metab · 2025-Jul-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. PMID 40678712 · World J Gastroenterol · 2025-Jul-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast cancer survivors (PACHA): protocol for a pilot cluster-randomized controlled trial. PMID 40660375 · Pilot Feasibility Stud · 2025-Jul-14 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Reasons for refusing high tibial osteotomy and the impact of virtual reality-based patient education: a prospective single-centre study. PMID 40660307 · J Orthop Surg Res · 2025-Jul-14 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Personalized, Texting-Based Conversational Agent to Address Sleep Disturbance in Individuals Who Have Survived Breast Cancer: Protocol for a Pilot Waitlist Randomized Controlled Trial. PMID 40658949 · JMIR Res Protoc · 2025-Jul-14 This is a protocol for a pilot randomized trial of a non-drug, digital cognitive behavioral therapy intervention for sleep disturbance in breast cancer survivors. It is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention, does not report efficacy results, and has no time-to-event primary or key secondary endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Influence of different photobiomodulation protocols on the prevention of chemotherapy-induced dysgeusia in breast cancer patients treated with Doxorubicin-Cyclophosphamide: a phase III, randomized, triple-blinded non-inferiority clinical trial. PMID 40658227 · Support Care Cancer · 2025-Jul-14 The record is a Phase III randomized trial in oncology with a drug intervention, but it does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The endpoints are toxicity, quality of life, and other non-survival outcomes. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Surgery or radiotherapy for early-stage cancer study (SORT) target trial protocol: stereotactic ablative radiotherapy (SABR) with curative intent versus surgical resection for early-stage non-small cell lung cancer (NSCLC). PMID 40659399 · BMJ Open · 2025-Jul-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Impact of proactively inviting people with advanced cancer to talk about the end of life: a randomised clinical trial protocol. PMID 40659391 · BMJ Open · 2025-Jul-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers. PMID 40652143 · J Cancer Res Clin Oncol · 2025-Jul-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study. PMID 40650694 · Cancer Immunol Immunother · 2025-Jul-12 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 2 Figure · 4 Panel · risk visible |
| Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. PMID 40570869 · Lancet · 2025-Jul-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| STUDY PROTOCOL FOR A DUAL-CENTER RANDOMIZED CONTROLLED TRIAL COMPARING LAPAROSCOPIC AND OPEN 'MINOR' LIVER RESECTIONS IN UKRAINIAN COLORECTAL CANCER PATIENTS WITH LIVER METASTASES. PMID 40674155 · Exp Oncol · 2025-Jul-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915. PMID 40645660 · J Immunother Cancer · 2025-Jul-11 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 3 Figure · 11 Panel · risk unclear |
| MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study. PMID 40641116 · Br J Psychiatry · 2025-Jul-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial. PMID 40220758 · Med · 2025-Jul-11 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America. PMID 40100744 · J Infect Dis · 2025-Jul-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA) for Preventing Recurrent Clostridioides difficile Infection. PMID 39172632 · J Infect Dis · 2025-Jul-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Chinese patients with advanced non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials. PMID 40640844 · World J Surg Oncol · 2025-Jul-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Artificial capnothorax versus single-lung ventilation in minimally invasive esophagectomy for esophageal cancer: A randomized controlled trial. PMID 40640078 · Chin Med J (Engl) · 2025-Jul-10 The study is a randomized oncology trial with time-to-event efficacy results, but it lacks a drug-containing intervention, which is a required criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypertensive disorders of pregnancy and perinatal outcomes: two prospective cohort studies of nulliparous women in India and Tanzania. PMID 40639854 · BMJ Glob Health · 2025-Jul-10 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study. PMID 40639850 · J Immunother Cancer · 2025-Jul-10 The report is an original result of a randomized, human oncology trial with a drug intervention and time-to-event efficacy endpoints. However, it is explicitly described as a 'pilot study', which is generally considered an early-phase (e.g., Phase II) or feasibility study, not a definitive Phase III/IIIb or Phase II/III trial. The instructions exclude early-phase studies and require explicit establishment of Phase III/IIIb or Phase II/III status, which is not met here. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Theory-based chatbot for promoting colorectal cancer screening in a community setting in Hong Kong: study protocol of a randomised controlled trial. PMID 40639841 · BMJ Open · 2025-Jul-10 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Relationship Between Third-Trimester Low Maternal Blood Pressure and Small-for-Gestational-Age Birth Weight in Pregnant Individuals With Mild Chronic Hypertension. PMID 40638923 · Obstet Gynecol · 2025-Jul-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Early-life undernutrition increases the risk of death from chronic diseases in adulthood: a population-based cohort study. PMID 40635115 · Glob Health Res Policy · 2025-Jul-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer. PMID 40454641 · N Engl J Med · 2025-Jul-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches. PMID 40440566 · J Clin Oncol · 2025-Jul-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE. PMID 40408605 · J Clin Oncol · 2025-Jul-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 2 Panel · risk unclear |
| Intravenous Tenecteplase before Thrombectomy in Stroke. PMID 40396577 · N Engl J Med · 2025-Jul-10 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| As-Needed Albuterol-Budesonide in Mild Asthma. PMID 40388330 · N Engl J Med · 2025-Jul-10 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma. PMID 40378359 · J Clin Oncol · 2025-Jul-10 命中用户提供的消化道肿瘤阳性参考集。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblepositive_reference | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. PMID 40311141 · J Clin Oncol · 2025-Jul-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial. PMID 40635107 · Exp Hematol Oncol · 2025-Jul-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Baseline factors affecting diabetic macular oedema resolution after intravitreal dexamethasone implant treatment: post hoc analysis of the MEAD study. PMID 40634898 · BMC Ophthalmol · 2025-Jul-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis. PMID 40732303 · Pharmaceuticals (Basel) · 2025-Jul-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomised controlled trial comparing low doses of aspirin in the prevention of pre-eclampsia (ASAPP): a study protocol. PMID 40633954 · BMJ Open · 2025-Jul-08 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Machine learning assisted adjustment boosts efficiency of exact inference in randomized controlled trials. PMID 40629057 · Sci Rep · 2025-Jul-08 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Association and predictive value of the triglyceride glucose-weight adjusted waist index for cardiovascular outcomes in patients with type 2 diabetes. PMID 40628839 · Sci Rep · 2025-Jul-08 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. PMID 40626388 · Cochrane Database Syst Rev · 2025-Jul-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer: The REAL Randomized Clinical Trial. PMID 40455621 · JAMA · 2025-Jul-08 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Estimated Theoretical Benefit of Aggressive LDL Lowering in Patients With Symptomatic Intracranial Atherosclerosis. PMID 40446174 · Neurology · 2025-Jul-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial. PMID 40710200 · Curr Oncol · 2025-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Endobiliary radiofrequency ablation in recurrence and unresectable Perihilar cholangiocarcinoma. PMID 40619373 · BMC Gastroenterol · 2025-Jul-07 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |